Radium-223 is associated with low rates of AEs, treatment discontinuation for bone metastatic CRPC
Of note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections.
Darolutamide found favorable for patients with nmCRPC in observational DEAR study
Investigators compared 3 second-generation androgen receptor inhibitors to determine real-world utilization of the drugs and examine the incidence of adverse events.
2-year update sustains promise of pembrolizumab plus abiraterone in chemo-naïve mCRPC
The addition of pembrolizumab has the potential to improve upon standard care with abiraterone acetate plus prednisone in men with metastatic castration-resistant prostate cancer.
2 Commerce Drive Cranbury, NJ 08512